leisure time -WSS

leisure time

author：focus 2025-10-02 22:40:57 - browse：9

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Researchers on aging grapple with how to calculate biological age

WSS

Humana’s losses in Medicare Advantage tank its stock

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Apple Watch's A

10 reasons why health care startups fail

Bird flu outbreak in cows is latest avian flu curveball

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

explore

leisure time

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Vertex non

The high cost of giving birth even with insurance

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Medical records are filled with copy

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Supreme Court strikes down use of affirmative action

CDC wastewater surveillance dashboard to track bird flu hotspots

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

explore

Making AI in medicine accessible to smaller, and rural hospitals

H5N1 communication has been strictly for the birds

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Humana’s losses in Medicare Advantage tank its stock

Medicare says breakthrough device reimbursement rule to come by summer

knowledge

leisure time

focus

focus